KALVISTA PHARMACEUTICALS INC

KalVista’s merger with Chiesi unlocks a $27.00 cash payout, new commercial synergies, and R&D growth – insiders liquidate options, investors eye post‑merger value.

KalVista insider buys 33,800 shares at $7.07—over 70% off—spurring a 17% social‑media spike and positive sentiment. Explore why exec confidence may signal EKTERLY’s growth potential and what this means for investors.

KalVista insider trades reveal executive confidence in its protease inhibitor pipeline and the biopharma market’s upside, yet highlight R&D risks and the need for careful data‑driven analysis.

KalVista insider buy signals optimism amid 28% monthly lift; clinical data show 72% response for KV‑PVI‑01 and Fast‑Track status—watch Phase IIb to gauge future valuation.

Venrock sells 5 M KalVista shares for $95 M, boosting cash and boosting clinical momentum for its mTNBC ADC while leaving investors to watch valuation and regulatory moves.

KalVista insider sale: VHCP3 sells 5.1 M shares, yet CEO & execs hold strong, reflecting routine portfolio moves amid solid EKTERLY approval and growth prospects. Click to see what it means for investors.

CEO Palleiko Benjamin L. buys 15,625 KalVista shares, hinting confidence as the company nears key protease‑inhibitor milestones. Explore the impact on investors.

KalVista’s chief development officer buys 1,774 shares, signaling confidence before EKTERLY’s AACC data—insider activity, social‑media buzz, and a $758 M market cap reveal.

KalVista insider buying signals CEO confidence in its biotech pipeline – a cautious, long‑term vote that may boost investor optimism.

KalVista CEO’s new share purchase signals confidence in EKTERLY and a promising oral protease‑inhibitor pipeline, hinting at future upside.